Histone lysine demethylases as targets for anticancer therapy.
about
A rationally-designed chimeric KDM1A/KDM1B histone demethylase tower domain deletion mutant retaining enzymatic activityTargeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesHistone demethylase LSD1 controls the phenotypic plasticity of cancer cellsEpigenetic therapy in gastrointestinal cancer: the right combinationEpigenetic treatment of solid tumours: a review of clinical trialsHistone demethylases in chromatin biology and beyondEpigenetic regulation by histone demethylases in hypoxiaHigh-throughput screening to identify inhibitors of lysine demethylasesStructure and function of dioxygenases in histone demethylation and DNA/RNA demethylationSubstituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylasesLSD1/KDM1A mutations associated to a newly described form of intellectual disability impair demethylase activity and binding to transcription factorsEpigenome-based personalized medicine in human cancerKDM1 class flavin-dependent protein lysine demethylasesPALB2: the hub of a network of tumor suppressors involved in DNA damage responsesGeminivirus-encoded TrAP suppressor inhibits the histone methyltransferase SUVH4/KYP to counter host defenseIdentification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data AnalysisTargeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.Epigenetic regulation of epithelial-mesenchymal transitionMelatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.The small molecule JIB-04 disrupts O2 binding in the Fe-dependent histone demethylase KDM4A/JMJD2A.Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumorsEpigenetic control of gene function in schistosomes: a source of therapeutic targets?Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas.Epigenetic drugs against cancer: an evolving landscape.The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.LSD1: biologic roles and therapeutic targeting.Histone Demethylases in Colon Cancer.Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies.Epigenetics in breast and prostate cancerTenovin-6-mediated inhibition of SIRT1/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem/progenitor cells.Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomesDynamic modulation of HSV chromatin drives initiation of infection and provides targets for epigenetic therapies.Extranucleosomal DNA enhances the activity of the LSD1/CoREST histone demethylase complex.The landscape and therapeutic relevance of cancer-associated transcript fusions.Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression.Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair.
P2860
Q24338644-090D9C9D-7388-488B-B030-4FA6216D1E7CQ26744441-27844C3D-FA57-4CEF-8998-7BCE81330ED2Q26745452-183E5C4F-7889-442C-8054-41720884D6EDQ26745709-F00D6ACE-74E7-4B7B-AB98-558A6D05C06EQ26773803-2E1351E7-A0EA-4992-A333-A263C4ED1431Q26777269-28EAC82D-6533-4DC2-84A2-5D452E07674EQ26825704-C8312F20-4538-4BC7-950D-8AC2850302C0Q26851462-871A3B30-803A-451B-A89C-FC034321EF02Q27012506-8E76A2C6-441D-4268-9A23-60883BF7A02DQ27704244-A439D0C9-52B3-4618-972C-A515B74B2344Q27704658-119BB923-21E5-42F6-910C-F515A43A8CA8Q28083951-44B113B8-0E0F-4ED7-9A19-58BD0EF4D3B8Q28084876-8722829C-BDA4-49AB-B135-FB134BE99951Q28243398-3B5B6C49-D9F2-4415-9162-F43B19607707Q28550284-85E50A51-22B1-49EE-AD01-7686032C80A3Q31068011-6C63683B-C927-4DC8-8266-539D35F889D3Q33598464-EE58D4BC-3944-490A-BBDE-1A76276EBB55Q33638726-292280B9-DF88-4785-AFAC-1AA63102C8DBQ33764436-9CFA5709-0A23-4391-B9D1-B1DED26F7D53Q33779673-D11F4544-400E-4F07-9441-708A7BB5D243Q33906319-4AA05EB7-7124-4947-BA32-DDB8C226CEABQ33906691-E747EA59-FFCE-4704-B3EF-3CA6B0C59B05Q33960142-2D47F808-B770-43A9-9F51-5B1F51B1D6AAQ34133068-A110FBBA-407C-489D-BE13-8EB32B6FC43AQ34159188-C714F6C5-C946-44A7-83CA-33FCEB3876D0Q34211637-31667C00-9BE3-4F5D-B65B-DD8C2FC07EB0Q34363489-629374FD-8086-4FEC-9F00-BDCFA1A34B22Q34431964-89356B94-F2DE-485F-9F2B-C9EE6EE58DEAQ34493999-A7E2811B-7223-4658-B1A2-DB53C1DB5677Q34678086-D3B64319-E24C-4E20-9483-68E2E1EEEF03Q34822197-62CE5936-44C0-40B8-AA2D-17308C6330C6Q35086759-AAFAA40C-7AF1-4FAE-A52F-7523EDAB67C1Q35190483-C034F2A6-26E1-47BC-9E63-70EF17C8BB49Q35380033-C72222E4-AC68-4623-8D00-FB6E627A379FQ35559725-0BA34EBE-BD05-41B6-8D1F-A6D3100BFA39Q35582225-378D0438-409A-4D10-95CE-2FABCE5F6DB0Q35656807-49B93F00-C07F-4F6B-98AA-C3E2CE9322F6Q35744353-9F5645D1-FC84-41CD-82D8-94B835FFDC49Q35910268-766928A2-2FC6-48F1-AACA-65F92D33BF18Q36038071-B4B19494-2BB1-4D8C-B84C-C039F6F5A064
P2860
Histone lysine demethylases as targets for anticancer therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Histone lysine demethylases as targets for anticancer therapy.
@en
type
label
Histone lysine demethylases as targets for anticancer therapy.
@en
prefLabel
Histone lysine demethylases as targets for anticancer therapy.
@en
P2860
P356
P1476
Histone lysine demethylases as targets for anticancer therapy.
@en
P2093
Karl Agger
P2860
P2888
P304
P356
10.1038/NRD4154
P577
2013-11-15T00:00:00Z